Evolent Health

Evolent Health, Inc. engages in the provision of health care delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolent Health excels in Q4 2022, eyes growth with Humana

Evolent Health posts strong financials, exceeding revenue and EBITDA targets.
Strategic partnerships and focus on organic growth drive value creation.
Challenges lie in maintaining growth momentum and effective execution.
Opportunities include margin expansion, capital optimization, and Humana partnerships.

Evolent Health surpasses Q1 expectations, eyes revenue growth opportunities

Evolent Health's Q1 performance exceeded expectations, driven by strong revenue growth and margin expansion initiatives. While facing challenges like revenue adjustments and Medicaid rebates, the company remains focused on capitalizing on growth opportunities through strategic partnerships and operational efficiencies.

Evolent Health excels in Q2, eyes $300M EBITDA target

Evolent Health's robust performance in Q2, strategic partnerships, and focus on organic growth position it well to achieve its financial targets.
Challenges lie in Medicaid membership declines, capital allocation optimization, and refinancing decisions amidst market uncertainties.
Opportunities in patient-centric care, CMS changes, and integrated entity approach offer avenues for growth and differentiation in the market.

Evolent Health surpasses Q3 expectations, eyes growth in specialty care

Evolent Health's Q3 performance exceeded expectations, driven by strong revenue growth and profitability, underpinned by strategic partnerships and a unique care model.
Despite challenges in ramping up Performance Suite adoption and maintaining cost control, the company's focus on growth and value creation positions it well for future success.
Opportunities in expanding specialty offerings and leveraging new partnerships highlight Evolent's growth potential and commitment to delivering value in the healthcare sector.

Evolent Health exceeds 2023 targets, eyes growth through partnerships

Evolent Health delivered strong financial results in Q4 2023, surpassing its 2023 targets and setting ambitious goals for 2024, driven by Specialty Care offerings and new revenue agreements.
While facing challenges related to medical utilization and new product launches, the company remains focused on organic growth and profitability, supported by a strategic approach to expansion.
Opportunities in cross-selling, new state expansions, and imaging capabilities position Evolent Health for continued growth and revenue diversification in the healthcare sector.

Evolent Health reports robust Q1 earnings, eyes margin improvements

Evolent Health's Q1 performance showcased strong revenue growth and EBITDA in line with guidance.
The company is optimistic about margin improvements, revenue expansion, and maintaining a balanced pipeline.
Challenges include margin impact from new go-lives and ongoing payer negotiations amid cost pressures.
Opportunities lie in improving gross margins, leveraging population changes, and focusing on cash flow expectations.

Evolent Health reports robust Q2 earnings, eyes growth opportunities ahead

Evolent Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives, and a positive outlook for future growth. The company's focus on revenue diversification, margin optimization, and disciplined financial management positions it well for continued success in the evolving healthcare landscape.

Evolent Health revises outlook after Q3 challenges, secures financing

Evolent Health navigated higher medical costs impacting Q3 results, leading to a revised outlook for 2024. Despite challenges in managing expenses and oncology costs, the company remains committed to growth and securing new revenue agreements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

CHICAGO--(BUSINESS WIRE)--More than 80 leaders from the Black faith community in Chicago gathered on Sept 29 to discuss ministering to their congregants' mental health.

Chicago Faith Leaders Plan Coordinated Sermons to Destigmatize Mental Health in Underserved Communities

WASHINGTON , Sept. 6, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), announced today that New Century Health CEO Dan McCarthy has been named Evolent Health President, effective September 15, 2022.

Evolent Health Announces Dan McCarthy Appointed as President, Frank J. Williams to Retire from Evolent's Board of Directors in 2023

Evolent Health acquires IPG and boosts its full-year guidance. On the back of its recent acquisition, the company's leverage returns to 2x.

Evolent Health: Improving Financials, But There's More

Does Evolent Health (EVH) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Evolent Health (EVH) a Strong Momentum Stock: Buy Now?

WASHINGTON , Aug. 10, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a health care company that delivers proven clinical solutions to payers and providers, today announced that Chief Executive Officer Seth Blackley and Vice President, Investor Relations Seth Frank will conduct investor meetings and host a presentation at the Canaccord Genuity 42nd Annual Growth Conference at The Intercontinental Boston Hotel, Boston, Mass., on Wednesday, August 10, 2022 at 4:30 p.m.

Evolent Health to Participate in the CG Growth Conference

The consensus price target hints at a 28.3% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 28% Upside in Evolent Health (EVH): Here's What You Should Know

The healthcare services provider recorded beats on both the top and bottom lines in its latest quarterly report.

Why Evolent Health Was Such a Healthy Stock Today

Evolent Health (EVH) delivered earnings and revenue surprises of 233.33% and 9.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Q2 Earnings and Revenues Beat Estimates

Evolent Health, Inc. (NYSE:EVH ) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Anne Samuel - JPMorgan Sandy Draper - Guggenheim David Larsen - BTIG Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Charles Rhyee - Cowen Operator Good evening and welcome to Evolent Health's Earnings Conference for the Second quarter ended June 30th, 2022. Your hosts for the call today from Evolent Health are Seth Blackley, Chief Executive Officer, and John Johnson, Chief Financial Officer.

Evolent Health, Inc. (EVH) CEO Seth Blackley on Q2 2022 Results - Earnings Call Transcript

Announces Four Operating Partner Additions WASHINGTON , Aug. 2, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended June 30, 2022. Highlights from the second quarter of 2022 announcement include: Quarter ended June 30, 2022: Revenue of $319.9 million, an increase of $97.9 million, or 44.1%, from the three months ended June 30, 2021.

Evolent Health Announces Second Quarter 2022 Results

Evolent Health earnings loom Tuesday night for the health care cost management firm. EVH stock is down but in buy range.

Evolent Health Is In Buy Zone Ahead Of Earnings Announcement

Company makes the ParityLIST for the third straight year. WASHINGTON , Aug. 1, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, has been named to the Parity.Org Best Companies for Women to Advance™ List for 2022.

Evolent Health Named to Parity.org's Best Companies for Women to Advance List 2022

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolent Health (EVH) Earnings Expected to Grow: Should You Buy?

Evolent Health (EVH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Evolent Health (EVH) a Good Fit for "Trend Investing"

Dave & Buster's

USA Truck

GAMCO Investors

Ingles Markets

Schnitzer Steel Industries Inc

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Dave & Busters, USA Truck See Activist Investor Action

WASHINGTON , July 15, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its second quarter 2022 operating results on Tuesday, August 2, 2022 after market close, with a conference call to follow at 5:00 p.m. Eastern Time.

Evolent Health, Inc. to Release Second Quarter Operating Results and Host Conference Call on Tuesday, August 2, 2022

Here's Why Evolent Health (EVH) is a Great Momentum Stock to Buy

Here is how Evolent Health (EVH) and KT Corp. (KT) have performed compared to their sector so far this year.

Has Evolent Health (EVH) Outpaced Other Computer and Technology Stocks This Year?

NEW YORK , June 30, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Evolent Health, Inc. (EVH), relating to its proposed merger with TPG Growth Iceman Parent, Inc., the parent entity of Implantable Provider Group, Inc., and TPG Growth V Iceman L.P. Click here for more information: https://www.monteverdelaw.com/case/evolent-health-inc.

Shareholder Alert - The M&A Class Action Firm Announces an Investigation of Evolent Health, Inc. - EVH

Evolent Health is a so-called value-based care provider, aiding payers and patients. The segment shows resilient growth, including Evolent, as no real profitability has been reported.

Evolent Health: Healthy Growth, But That Is About It

Investors had a muted, yet positive, reaction to news of the company's latest acquisition.

Why Evolent Health Stock Crept Higher Today

- Expected to Accelerate Evolent Health's Position as a Leading Provider of Value-Based Specialty Care Solutions - Expands Evolent's Value-Based Specialty Care Solutions Portfolio to Musculoskeletal Conditions - Expected to be Immediately Accretive to Adjusted EBITDA Margins and Cash Flow - Diversifies Customer Mix and Accelerates Entry into Commercial Line of Business WASHINGTON , June 29, 2022 /PRNewswire/ --  Evolent Health, Inc. ("Evolent" or "the Company") (NYSE: EVH) today announced that it has entered into a definitive agreement to acquire IPG, a leading technology and services company providing surgical management solutions for musculoskeletal conditions, from TPG Growth, the middle market and growth equity platform of alternative asset firm TPG, for $375 million plus additional contingent consideration of up to $87 million. Upon close the IPG team and platform will be integrated into New Century Health.

EVOLENT HEALTH TO ACQUIRE IPG

Evolent Health (EVH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Evolent Health (EVH) is on the Move, Here's Why the Trend Could be Sustainable

The mean of analysts' price targets for Evolent Health (EVH) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Evolent Health (EVH) Could Rally 38%: Here's is How to Trade

Wilmington, Delaware--(Newsfile Corp. - May 27, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Evolent Health, Inc. (NYSE: EVH) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-evolent-health-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on...

News for Evolent Health Stock (EVH)